SLN Projected Dividend Yield
ADR (Sponsored)/Silence Therapeutics Plc ( NASDAQ : SLN )Silence Therapeutics is a biotechnology company focused on discovering and developing molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with unmet medical need. Co.'s wholly owned pipeline is focused in three therapeutic areas of unmet need: cardiovascular disease, hematology and rare diseases. Co.'s wholly owned product candidates are: SLN360, which is an siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood; and SLN124, which is an siRNA molecule designed to treat erythropoiesis. 20 YEAR PERFORMANCE RESULTS |
SLN Dividend History Detail SLN Dividend News SLN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |